|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Treatment of Recurrent Refractory Pediatric Pre-B Acute Lymphoblastic Leukemia Using Inotuzumab Ozogamicin Monotherapy Resulting in CD22 Antigen Expression Loss as a Mechanism of Therapy Resistance.
|
30807395 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma.
|
31753002 |
2019 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma.
|
31753002 |
2019 |
|
Refractory Acute Lymphoblastic Leukemia
|
0.040 |
Biomarker
|
disease |
BEFREE |
Immunotherapies targeting CD19 (blinatumomab) and CD22 (inotuzumab ozogamicin) have demonstrated higher complete response rates and improved survival compared with chemotherapy in relapsed/refractory acute lymphoblastic leukemia (ALL), and are now standard of care in the relapsed setting.
|
31766014 |
2019 |
|
Refractory Acute Lymphoblastic Leukemia
|
0.040 |
Biomarker
|
disease |
BEFREE |
We examined treatment with sequential infusion of humanized CD19-modified and CD22-modified CAR-T cells in a patient with relapsed ALL previously exposed to murine-derived anti-CD19 CAR-T cells.
|
30988623 |
2019 |
|
Refractory Acute Lymphoblastic Leukemia
|
0.040 |
Biomarker
|
disease |
BEFREE |
Chimeric antigen receptor T-cell (CART) therapy targeting CD22 induces remission in 70% of patients with relapsed/refractory acute lymphoblastic leukemia (ALL).
|
31110075 |
2019 |
|
Burkitt Leukemia
|
0.040 |
Biomarker
|
disease |
BEFREE |
Finally, patients with B-cell ALL are more amendable to available targeted therapies, such as Philadelphia chromosome-positive and some Philadelphia chromosome-like ALL cases to ABL-class tyrosine kinase inhibitors, and CD19-positive and CD22-postive B-cell ALL cases to a variety of immunotherapies.
|
30842058 |
2019 |
|
Neoplasm, Residual
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
The anti-CD22 recombinant immunotoxin Moxetumomab Pasudotox can achieve MRD-negative CR in multiply relapsed HCL without chemotherapy toxicities and was FDA approved in 2018 as Lumoxiti.
|
31068044 |
2019 |
|
Pre B-cell acute lymphoblastic leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia.
|
31110217 |
2019 |
|
Refractory Childhood Acute Lymphoblastic Leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Chimeric antigen receptor T-cell (CART) therapy targeting CD22 induces remission in 70% of patients with relapsed/refractory acute lymphoblastic leukemia (ALL).
|
31110075 |
2019 |
|
Refractory Childhood Acute Lymphoblastic Leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Immunotherapies targeting CD19 (blinatumomab) and CD22 (inotuzumab ozogamicin) have demonstrated higher complete response rates and improved survival compared with chemotherapy in relapsed/refractory acute lymphoblastic leukemia (ALL), and are now standard of care in the relapsed setting.
|
31766014 |
2019 |
|
Refractory Childhood Acute Lymphoblastic Leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
We examined treatment with sequential infusion of humanized CD19-modified and CD22-modified CAR-T cells in a patient with relapsed ALL previously exposed to murine-derived anti-CD19 CAR-T cells.
|
30988623 |
2019 |
|
Refractory Adult Acute Lymphoblastic Leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Immunotherapies targeting CD19 (blinatumomab) and CD22 (inotuzumab ozogamicin) have demonstrated higher complete response rates and improved survival compared with chemotherapy in relapsed/refractory acute lymphoblastic leukemia (ALL), and are now standard of care in the relapsed setting.
|
31766014 |
2019 |
|
Refractory Adult Acute Lymphoblastic Leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Chimeric antigen receptor T-cell (CART) therapy targeting CD22 induces remission in 70% of patients with relapsed/refractory acute lymphoblastic leukemia (ALL).
|
31110075 |
2019 |
|
Refractory Adult Acute Lymphoblastic Leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
We examined treatment with sequential infusion of humanized CD19-modified and CD22-modified CAR-T cells in a patient with relapsed ALL previously exposed to murine-derived anti-CD19 CAR-T cells.
|
30988623 |
2019 |
|
Rheumatoid Arthritis
|
0.020 |
Biomarker
|
disease |
BEFREE |
We show that STALs that codisplay a high affinity CD22 glycan ligand and synthetic citrullinated antigen (CCP STALs) can prevent ACPA production from RA patients' memory B-cells in vitro.
|
30835424 |
2019 |
|
Childhood B Acute Lymphoblastic Leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia.
|
31110217 |
2019 |
|
Adult B Acute Lymphoblastic Leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia.
|
31110217 |
2019 |
|
Refractory Hairy Cell Leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Moxetumomab pasudotox is a recombinant CD22-targeting immunotoxin that has recently been approved by the United States Food and Drug Administration for the treatment of relapsed or refractory hairy cell leukemia.
|
30917739 |
2019 |
|
Arthus Reaction
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results demonstrate that CD22 and CD72 expression contribute to the development of the reverse Arthus reaction model and CD22 and CD72 might be therapeutic targets for human IC-mediated diseases.
|
31262443 |
2019 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Since the first approval of gemtuzumab ozogamicin (Mylotarg; Pfizer; CD33 targeted), two additional antibody-drug conjugates (ADC), brentuximab vedotin (Adcetris; Seattle Genetics, Inc.; CD30 targeted) and inotuzumab ozogamicin (Besponsa; Pfizer; CD22 targeted), have been approved for hematologic cancers and 1 ADC, trastuzumab emtansine (Kadcyla; Genentech; HER2 targeted), has been approved to treat breast cancer.
|
30979742 |
2019 |
|
Immune Complex Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
To elucidate the roles of CD22 and CD72 in the development of IgG-mediated type III hypersensitivity reactions.
|
31262443 |
2019 |
|
Lymphoproliferative Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
We employed both immortalized and primary cells derived from CD22-positive lymphoproliferative disorders to investigate the signaling pathways contributing to IO sensitivity or resistance.
|
30834235 |
2019 |
|
Hypersensitivity reaction mediated by immune complex
|
0.010 |
Biomarker
|
disease |
BEFREE |
To elucidate the roles of CD22 and CD72 in the development of IgG-mediated type III hypersensitivity reactions.
|
31262443 |
2019 |
|
Capillary Leak Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Also, anti-cancer agents, including IL-2 + imatinib mesylate (three studies) and anti-CD22 monoclinal antibodies (mAb) (four studies), showed a dose-dependent increase in the incidence of CLS.
|
30691103 |
2019 |